AlphaMedixTM is a somatostatin receptor targeting peptide radiolabeled with 212Pb. Somatostatin receptors are overexpressed in most neuroendocrine tumors, a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract and pancreas, but can also occur in other tissues including thymus, lung, and other uncommon sites such as ovaries, heart, and prostate.
After the promising results of the Phase 1 clinical trial launched early 2018, a Phase 2 was initiated late 2021 to assess the efficacy of AlphamedixTM in the treatment of neuroendocrine tumors. The study is currently recruiting patients in the US.
Find out more on the ClinicalTrials.gov website.
Our partners: RadioMedix and Excel Diagnostics & Nuclear Oncology Center.
212Pb-PRIT program (pre-targeted radio immunotherapy) is a joint development program with Roche to create a novel, advanced alpha radioimmunotherapy platform to target and kill cancer cells with a specific focus on malignant disease with a high unmet medical need.
Our partner: Roche is a Swiss pharmaceutical company and the world leader in the oncology field. Orano Med and Roche launched a strategic alliance in 2012 to develop a new platform. As part of this new alliance, Roche and Orano Med have built a research laboratory located in France dedicated to the co-development of targeted alpha therapy.
Pb-NNV003 is a 212
Pb-conjugated anti-CD37 antibody under development for the treatment of leukemia, orphan diseases with still significant unmet medical need. CD-37 is an interesting target as it is widely expressed in a number of hematological malignancies, including leukemia.
Our partner: Nordic Nanovector is a Norwegian biopharmaceutical company dedicated to extending and improving the lives of patients with hematological cancers through the development and commercialization of innovative targeted therapeutics. Nordic Nanovector and Orano Med signed a collaboration agreement in 2016 to investigate the potential of a 212Pb-conjugated anti-CD37 antibody.
212Pb-GRPR is a 212Pb-conjugated anti-GRPR (Gastrin-Releasing Peptide Receptor) developed par Orano Med targeting different types of solid tumors including several breast and prostate cancers tumor types. Late 2021, and upon promising preclinical results, Orano Med submitted and IND (Investigational New Drug) to the FDA for an entry into Phase 1 clinical trials. This study will enroll patients in the US.
212Pb-PDC is a program combining Orano Med’s technology with Cellectar Bioscience cancer cells targeting technology to create a novel oncologic therapy. The collaboration will focus on the development of novel phospholipid drug conjugates (PDC™) utilizing Orano Med’s lead-212, conjugated to Cellectar’s phospholipid ether (PLE).
Our partner: Cellectar Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Cellectar’s core objective is to leverage its proprietary phospholipid drug conjugates™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects.
Due to longer accumulation of antibodies targeting antigens expressed by solid tumors (usually several days), Orano Med is developing new approaches to label 212Pb to peptides offering a more suitable pharmacokinetic profile for 212Pb half-life. Orano Med is working on several targets expressed in various type of cancers.